

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934**

**For the Month of: December 2016**

**Commission File Number: 001-37847**

**MOTIF BIO PLC**

(Exact name of Registrant as specified in its charter)

**125 Park Avenue  
25<sup>th</sup> Floor, Suite 2622  
New York, New York 10011**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On December 5, 2016, Motif Bio plc (the "Company") issued a press release announcing the publication of a Circular and Notice of General Meeting to the Company's shareholders, a copy of which is attached as Exhibit 99.1 to this Report on Form 6-K.

The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant's registration statements or other filing with the Commission.

**Exhibits**

<b>Exhibit Number</b>	<b>Exhibit Table</b>
99.1	Press Release issued by Motif Bio plc, dated December 5, 2016, announcing the publication of a Circular and Notice of General Meeting.

2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: December 5, 2016

**MOTIF BIO PLC**

By: /s/ Graham Lumsden  
Graham Lumsden  
Chief Executive Officer

3



**Motif Bio plc**  
 (“Motif Bio” or the “Company”)

5 December 2016

**PUBLICATION OF CIRCULAR AND NOTICE OF GENERAL MEETING**

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on Friday 2 December 2016 it sent to Shareholders a circular and notice of General Meeting to be held at the offices of Reed Smith LLP at The Broadgate Tower, 20 Primrose Street, London EC2A 2RS on 21 December 2016 at 2.00 p.m. at which the following Resolutions will be proposed:

- (A) Resolution 1, which will be proposed as an ordinary resolution, is to authorise the Directors to allot relevant securities up to an aggregate nominal value of £313,938.23 in connection with the exercise of various share options, warrants and convertible securities granted by the Company between 1 April 2015 and the date of this document;
- (B) Resolution 2, which will be proposed as an ordinary resolution, is to authorise the Directors to allot relevant securities otherwise than for the purposes set out in resolution 1, up to an aggregate nominal amount of £270,965.62;
- (C) Resolution 3, which will be proposed as a special resolution and which is subject to the passing of resolution 1, is to disapply statutory pre-emption rights, provided that such authority shall be limited to, *inter alia*, the allotment of equity securities in connection with the exercise of various share options, warrants and convertible securities granted by the Company between 1 April 2015 and the date of this document; and
- (D) Resolution 4, which will be proposed as a special resolution and which is subject to the passing of resolution 2, is to disapply statutory pre-emption rights, provided that such authority shall be limited to, *inter alia*, the allotment of equity securities otherwise than in connection with the purposes set out in resolution 1 up to an aggregate nominal amount of £270,965.62.

The circular together with notice of General Meeting, is available on the Company’s website at [www.motifbio.com](http://www.motifbio.com). Capitalised terms used herein but not defined have the same meanings as set out in the circular.

**For further information please contact:**

<b>Motif Bio plc</b>	info@motifbio.com
Richard Morgan (Chairman)	
Graham Lumsden (Chief Executive Officer)	
<b>Zeus Capital Limited (NOMAD &amp; BROKER)</b>	+44 (0)20 3829 5000
Phil Walker/Giles Balleny	
Dominic Wilson	
<b>Northland Capital Partners Limited (BROKER)</b>	+44 (0)20 3861 6625
Patrick Claridge/ David Hignell	
John Howes/ Rob Rees (Broking)	
<b>Walbrook PR Ltd. (FINANCIAL PR &amp; IR)</b>	+44 (0)20 7933 8780 or motifbio@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893
Mike Wort	Mob: +44 (0)7900 608 002
<b>MC Services AG (EUROPEAN IR)</b>	
Raimund Gabriel	+49 (0)89 210 2280

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.